Day: March 8, 2021

MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) — Opus One Gold Corp. Inc. (OOR: TSXV) (“Opus One Gold” or the “Company”), a mining exploration company focused on exploring for high quality gold and base metal assets in accessible areas is pleased to announce that drilling is progressing on schedule on its Noyell Gold project, located 25 km south of the town of Matagami, Abitibi, Quebec.The target area consists of a poorly explored portion of the Casa-Berardi-Douay-Cameron deformation zone which host the Casa Berardi gold mine (actual gold producer) and the Vezza Gold Mine (past producer). The Noyell property is located 10 km to the east of the Vezza gold Mine, in the same geological environment.  As of now, two-third of our planned 5,000 m drilling program has been completed. The company is happy to report that most drill holes have...

Company announcement, inside information, Helsinki, 8 March 2021 at 3.15 PM (EET)Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issueNexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces with reference to the company announcement published earlier today regarding a subscription rights issue totaling approximately EUR 6.6 million , that the Company has prepared an EU growth prospectus which the Finnish Financial Supervisory Authority (FIN-FSA) has approved on 8 March 2021. The Board of Directors of Nexstim has resolved to publish the EU growth prospectus on 8 March 2021 and it shall be notified to Sweden.Finnish version of the EU growth Prospectus will be available approximately on 8 March 2021 on the Nexstim’s website at http://www.nexstim.com/investors/rights-issue-2021 and...

Yhtiötiedote, sisäpiiritieto, Helsinki, 8.3.2021 klo 15.15 (EET)Nexstim Oyj julkistaa EU:n kasvuesitteen 6,6 miljoonan euron merkintäoikeusannistaNexstim Oyj (NXTMH:HEX, NXTMS:STO) (”Nexstim” tai ”Yhtiö”) ilmoittaa viitaten aiemmin tänään julkaistuun yhtiötiedotteeseen liittyen noin 6,6 miljoonan euron suuruiseen merkintäoikeusantiin, että Yhtiö on laatinut osakeantiin liittyen EU:n kasvuesitteen, jonka Finanssivalvonta on hyväksynyt 8.3.2021. Yhtiön Hallitus on päättänyt julkaista EU:n kasvuesitteen 8.3.2021 ja se notifioidaan Ruotsiin.Suomenkielinen EU:n kasvuesite on saatavilla arviolta 8.3.2021 lähtien Nexstimin verkkosivustolla osoitteessa www.nexstim.com/investors/rights-issue-2021 ja Yhtiön rekisteröidyssä toimipaikassa osoitteessa Elimäenkatu 9 B, 00510 Helsinki. Lisäksi suomenkielinen EU:n kasvuesite on saatavilla Nasdaq Helsingin...

Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 15.15 (EET)Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euroNexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar med hänvisning till bolagets företagsmeddelande utgiven tidigare i dag, om en företrädesemission av cirka 6,6 miljoner euro att bolaget har upprättat ett EU-tillväxtprospekt som Finansinspektionen godkände den 8 mars 2021. Bolagets styrelse beslutade att offentliggöra EU-tillväxt prospektet den 8 mars 2021 och det ska notifieras till Sverige.EU-tillväxtprospektet på finska läggs omkring den 8 mars 2021 ut på Nexstims webbplats på www.nexstim.com/investors/rights-issue-2021 och tillhandahålls också på bolagets registrerade adress på Elimäkigatan 9 B, 00510 Helsingfors. Dessutom görs EU-tillväxtprospektet...

SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Lisa Johnson-Pratt, M.D., Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), to its Board of Directors.“We are very pleased to welcome Lisa to TRACON’s Board of Directors,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. “She is a physician who has focused the majority of her career on the commercialization of innovative products, including Gardasil® and Singulair® at Merck, prior...

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ETNorwood, MA, March 08, 2021 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it will report its fourth quarter and year-end financial results on Monday, March 15th. Corbus management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.About Corbus Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a...

BOCA RATON, Fla., March 08, 2021 (GLOBE NEWSWIRE) — Xeriant, Inc. (OTC PINK: XERI), a new aerospace technology holding company, announced today that it has signed a letter of intent to form a strategic alliance with Mente Systems Inc. (DBA TheIncLab), an award-winning artificial intelligence (AI) company based in McLean, Virginia, and a leading innovator in the development of AI-enabled systems focused on the human experience, called AI+X. As part of the agreement, Xeriant plans to make a strategic investment in TheIncLab as it expands its operations and array of technology products.Established in 2015, TheIncLab designs and builds rapidly deployable, intelligent systems that optimize the interface between humans, technology, data and the environment, serving Fortune 500 companies in a wide range of industries, including aerospace...